ISPOR. 2022-2023 Top 10 HEOR Trends Report, 2022, https://www.ispor.org/heor-resources/about-heor/top-10-heor-trends (dostęp: 12.05.2022).
Gavrielov-Yusim N., Friger M., Use of Administrative Medical Databases in Population-based Research, "Journal of Epidemiology and Community Health" 2014; 68 (3): 283-287.
Zarebska-Michaluk D., Jaroszewicz J., Rogalska M., et al., Effectiveness of Tocilizumab With and Without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study, "Journal of Inflammation Research” 2021; 14: 3359-3366.
Offord C., The Surgisphere Scandal: What Went Wrong? Scientist, październik 2020, https://www.the-scientist.com/features/thesurgisphere-scandal-what-went-wrong—67955 (dostęp: 12.05.2022).
How Real World Evidence Was Used to Support Approval of Ibrance for Male Breast Cancer, "The Cancer Letter” 2019; 45: 7-10, https://cancerletter.com/the-cancer-letter/20190419_2/ (dostęp: 20.02.2022).
Flatiron Health, Flatiron Health Real-World Data Support FDA Approval of New Dosing Regimen for ERBITUX® (Cetuximab), komunikat prasowy, https://flatiron.com/press/press-release/flatiron-health-real-world-data-support-fdaapproval-of-new-dosingregimen-for-erbitux-cetuximab/ (dostęp: 20.02.2022).
EMA, Assessment Report on Provisional Measures - Zinbryta. 6 March 2018 EMA/159031/2018, https://www.ema.europa.eu/en/medicines/human/referrals/zinbryta (dostęp: 20.02.2022).
Narodowy Fundusz Zdrowia, Sprawozdania z działalności NFZ, https://www.nfz.gov.pl/bip/dzialalnosc-nfz/ (dostęp: 25.03.2022).
Holko P., REQUIREMENT-IBD: Real-World Consequences of Biologic Treatments for Inflammatory Bowel Diseases Based on the Analysis of the Databases of the National Health Fund, doi: 10.17605/OSF.IO/WQBRN.
Holko P., Kawalec P., Pilc A., Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist, "Pharmacoeconomics” 2018; 36 (7): 853-865.
Zagórowicz E., Walkiewicz D., Kucha P., et al., Epidemiology of Inflammatory Bowel Disease in Poland 2009-2020: Nationwide Data, "Polish Archives of Internal Medicine” 2022, doi: 10.20452/pamw.16194.
Holko P., Kawalec P., Stawowczyk E., Prevalence and Drug Treatment Practice of Inflammatory Bowel Diseases in Poland in the Years 2012-2014 - An Analysis of Nationwide Databases, "European Journal of Gastroenterology and Hepatology” 2018; 30 (4): 456-464.
Tuśnio N., Fichna J., Nowakowski P., Comparison of the Efficacy of Available Statistical Methods for Prediction of the Hospitalizations Number: Proof of Concept and Validation Based on the Analysis of Polish National Health Fund Data in The Years 2009-2017, "Folia Medica Cracoviensia” 2019; 59 (1): 89-100.
Holko P., Kawalec P., Pilc A., Impact of Biologic Treatment of Crohn’s Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland, "Frontiers in Pharmacology” 2018; 9: 621.
Kaniewska M., Moniuszko A., Rydzewska G., The Efficacy and Safety of the Biosimilar Product (Inflectra®) Compared to the Reference Drug (Remicade®) in Rescue Therapy in Adult Patients with Ulcerative Colitis, "Przegląd Gastroenterologiczny”2017; 12 (3): 169-174.
Eder P., Kłopocka M., Wiśniewska-Jarosińska M., et al., Possible Undertreatment of Women with Crohn Disease in Poland. A Subgroup Analysis from a Prospective Multicenter Study of Patients on Anti-Tumor Necrosis Factor Therapy, "Polish Archives of Internal Medicine” 2017; 127 (10): 674-680.
Stawowczyk E., Kawalec P., Pilc A., Cost-Utility Analysis of 1-Year Treatment with Adalimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland, "European Journal of Clinical Pharmacology” 2016 Nov; 72 (11): 1319-1325.
Stawowczyk E., Kawalec P., Pilc A., Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland, "Pharmacotherapy” 2016 May; 36 (5): 472-481.
Kubielas G., Diakowska D., Uchmanowicz I., Survival Analysis of Patients with Acute Coronary Syndrome Receiving Comprehensive Coordinated Care after Myocardial Infarction (KOS-Zawał), "Kardiologia Polska” 2022; 80 (3): 415-321, doi: 10.33963/KP.a2022.0035.
Januszewicz W., Witczak K., Wieszczy P., et al., Prevalence and Risk Factors of Upper Gastrointestinal Cancers Missed During Endoscopy: A Nationwide Registry-Based Study, "Endoscopy” 2022; 54 (7): 653-660, doi: 10.1055/a-1675-4136.
Kostera-Pruszczyk A., Napiórkowski Ł., Szymańska K., et al., Spinal Muscular Atrophy: Epidemiology and Health Burden in Children - A Polish National Healthcare Database Perspective Before Introduction of SMA-Specific Treatment, "Neurologia i Neurochirurgia Polska” 2021; 55 (5): 479-484, doi: 10.5603/PJNNS.a2021.0074.
Pietrzykowski Ł., Kasprzak M., Michalski P., et al., The Influence of Patient Expectations on Adherence to Treatment Regimen after Myocardial Infarction, "Patient Education and Counseling” 2022; 105 (2): 426-431, doi: 10.1016/j.pec.2021.05.030.
Kardas P., Urbański F., Lichwierowicz A., et al., Prevalence and Age Structure of Polypharmacy in Poland: Results of the Analysis of the National Real-World Database of 38 Million Citizens, "Frontiers in Pharmacology” 2021; 12: 655364, doi: 10.3389/fphar.2021.655364.
Wilk M., Waśko-Grabowska A., Skoneczna I., et al., Angiotensin System Inhibitors May Improve Outcomes of Patients With Castration-Resistant Prostate Cancer During Abiraterone Acetate Treatment-A Cardio-Oncology Study, "Frontiers in Oncology” 2021; 11: 664741, doi: 10.3389/fonc.2021.664741.
Wyszomirska K., Wyszomirski A., Brzeziński M., et al., Home Artificial Nutrition in Polish Children: An Analysis of 9-Year National Healthcare Provider Data, "Nutrients” 2021; 13 (3): 1007. Published 2021 Mar 21, doi: 10.3390/nu13031007.
Deja M.A., Malinowski M., Widenka K., et al., Repair or Replacement for Secondary Mitral Regurgitation: Results From Polish National Registry, "Annals of Thoracic Surgery” 2022; 113 (1): 146-156, doi: 10.1016/j.athoracsur.2020.12.059.
Tomasik A., Nabrdalik K., Kwiendacz H., et al., Effect of Diabetes Mellitus and Left Ventricular Perfusion on Frequency of Development of Heart Failure and/or All-cause Mortality Late After Acute Myocardial Infarction, "American Journal of Cardiology” 2021; 140: 25-32, doi: 10.1016/j.amjcard.2020.10.051.
Kapica-Topczewska K., Collin Fz., Tarasiuk J., et al., John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis, "European Journal of Neurology” 2020; 83 (5): 487-492, doi: 10.1159/000510849.
Wita K., Kułach A., Sikora J., et al., Managed Care after Acute Myocardial Infarction (MC-AMI) Reduces Total Mortality in 12-Month Follow-Up-Results from a Poland’s National Health Fund Program of Comprehensive Post-MI Care-A Population-Wide Analysis, "Journal of Clinical Medicine” 2020; 9 (10): 3178, doi: 10.3390/jcm9103178.
Pietrzykowski Ł., Michalski P., Kosobucka A., et al., Medication Adherence and its Determinants in Patients After Myocardial Infarction, "Scientific Reports” 2020; 10 (1): 12028, doi: 10.1038/s41598-020-68915-1.
Kozioł M., Nowak M.S., Udziela M., et al., First Nation-Wide Study of Diabetic Retinopathy in Poland in the Years 2013- 2017, "Acta Diabetologica” 2020; 57 (10): 1255-1264, doi: 10.1007/s00592-020-01540-6.
Wita K., Kułach A., Wita M., et al., Managed Care After Acute Myocardial Infarction (KOS-Zawał) Reduces Major Adverse Cardiovascular Events by 45% in 3-Month Follow-Up - Single-Center Results of Poland’s National Health Fund Program of Comprehensive Post-Myocardial Infarction Care, "Archives of Medical Science” 2019; 16 (3): 551-558, doi: 10.5114/aoms.2019.85649.
Kapica-Topczewska K., Collin F., Tarasiuk J., et al., Clinical and Epidemiological Characteristics of Multiple Sclerosis Patients Receiving Disease-Modifying Treatment in Poland, "Neurologia i Neurochirurgia Polska” 2020; 54 (2): 161-168, doi: 10.5603/PJNNS.a2020.0020.
Małyszczak A., Łukawska A., Dyląg I., et al., Blood Platelet Count at Hospital Admission Impacts Long-Term Mortality in Patients with Acute Coronary Syndrome, "Cardiology” 2020; 145 (3): 148-154, doi: 10.1159/000505640.
Zuber-Laskawiec K., Kubicka-Trzaska A., Karska-Basta I., et al., Non-Responsiveness and Tachyphylaxis to Anti-Vascular Endothelial Growth Factor Treatment in Naive Patients with Exudative Age-Related Macular Degeneration, "Journal of Physiology and Pharmacology” 2019; 70 (5): 10.26402/jpp.2019.5.13, doi: 10.26402/jpp.2019.5.13.
Wierzba W., Wierzba A., Śliwczyński A., et al., Analysis of National Health and Insurance Registers for All-Cause Mortality in Patients with Heart Failure with and without Diabetes Mellitus in Poland in 2012, "Medical Science Monitor” 2019; 26:e921138, doi: 10.12659/MSM.921138.
Brzozowska M., Wierzba W., Śliwczyński A., et al., Analysis of the Survival of Patients Receiving Systemic Treatment for Melanoma of the Skin: A Retrospective Population Study with Patients Treated in Poland in 2011-2015, "Postępy Dermatologii i Alergologii” 2019; 36 (4): 438-441, doi: 10.5114/ada.2019.83368.
Brzozowska M., Wierzba W., Szafraniec-Buryło S., et al., Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland, "Medical Science Monitor” 2019; 25: 3846-3853, doi: 10.12659/MSM.914517.
Bandurska E., Damps-Konstańska I., Popowski P., et al., Cost-Effectiveness Analysis of Integrated Care in Management of Advanced Chronic Obstructive Pulmonary Disease (COPD), "Medical Science Monitor” 2019; 25: 2879-2885, doi: 10.12659/MSM.913358.
Brzozowska M., Wierzba W., Szafraniec-Buryło S., et al., Overall Survival of Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer Treated with Erlotinib, Gefitinib or Afatinib Under Drug Programmes in Poland - Real-World Data, "Archives of Medical Science” 2019; 17 (6): 1618-1627, doi: 10.5114/aoms.2018.80362.
Symonides B., Śliwczyński A., Gałązka Z., et al., Short- and Long-Term Survival After Open Versus Endovascular Repair of Abdominal Aortic Aneurysm-Polish Population Analysis, "PLoS One” 2018; 13 (6): e0198966, doi: 10.1371/journal.pone.0198966.
Tłustochowicz M., Śliwczyński A.M., Brzozowska M., et al., Sequentiality of Treatment in the Rheumatoid Arthritis Drug Programme in the Years 2009-2014, "Archives of Medical Science” 2018; 14 (3): 569-571, doi: 10.5114/aoms.2016.58924.
Szyluk K., Jasiński A., Niemiec P., et al., Male Gender and Age Range 20-29 Years Are the Most Important Non-Modifiable Risk Factors for Recurrence After Primary Post-Traumatic Shoulder Dislocation, "Knee Surgery, Sports Traumatology, Arthroscopy”2018; 26 (8): 2454-2464, doi: 10.1007/s00167-018-4924-4.
Tomasik A., Młyńczak T., Nowak E., et al., Quantitative Myocardial Blush Score (QuBE) Allows the Prediction of Heart Failure Development in Long-Term Follow-Up in Patients With ST-Segment Elevation Myocardial Infarction: Proof of Concept Study, "Journal of Cardiology” 2019; 26 (4): 322-332, doi: 10.5603/CJ.a2017.0129.
Brzozowska M., Wierzba W., Śliwczyński A., et al., Analysis of Survival of Patients Treated with Vemurafenib, Ipilimumab and Dabrafenib for Advanced Skin Melanoma in Daily Clinical Practice (Real-World Data): Retrospective Analysis of Patients Treated Under Drug/Reimbursement Programmes In Poland In 2013-2016, "Melanoma Research” 2018; 28 (1): 52-55, doi: 10.1097/CMR.0000000000000408.
Jacheć W., Tomasik A., Polewczyk A., et al., Impact of ICD Lead on the System Durability, Predictors of Long-Term Survival Following ICD System Extraction, "Pacing and Clinical Electrophysiology” 2017; 40 (10): 1139-1146, doi: 10.1111/pace.13173.
Gąsior M., Pres D., Wojakowski W., et al., Causes of Hospitalization and Prognosis in Patients with Cardiovascular Diseases. Secular Trends in the Years 2006-2014 According to the Silesian Cardiovascular (SILCARD) Database, "Polish Archives of Internal Medicine” 2016; 126 (10): 754-762, doi: 10.20452/pamw.3557.
Kozierkiewicz A., Jach R., Basta T., et al., Skuteczność i koszty leczenia raka jajnika w PoIsce - ujęcie regionalne [Efficacy and Costs of Ovarian cCancer Therapy in Poland - Regional Approach], "Ginekologia Polska” 2015; 86 (8): 582-589.
Kubica A., Obońska K., Kasprzak M., et al., Prediction Of High Risk Of Non-Adherence To Antiplatelet Treatment, "Kardiologia Polska” 2016; 74 (1): 61-67, doi: 10.5603/KP.a2015.0117.
Opolski G., Januszkiewicz Ł., Szczerba E., et al., Readmissions and Repeat Procedures after Catheter Ablation for Atrial Fibrillation, "Journal of Cardiology” 2015; 22 (6): 630-636, doi: 10.5603/CJ.a2015.0037.
Śliwczyński A., Brzozowska M., Iltchew P., et al., Epidemiology of Asthma in Poland in Urban and Rural Areas, Based on Provided Health Care Services, "Pneumonologia i Alergologia Polska” 2015; 83 (3): 178-187, doi: 10.5603/PiAP.2015.0029.
Gierlotka M., Zdrojewski T., Wojtyniak B., et al., Incidence, Treatment, In-Hospital Mortality and One-Year Outcomes of Acute Myocardial Infarction in Poland in 2009-2012 - Nationwide AMI-PL Database, "Kardiologia Polska” 2015; 73 (3): 142-158, doi: 10.5603/KP.a2014.0213.
Sielski J., Janion-Sadowska A., Sadowski M., et al., Differences in Presentation, Treatment, and Prognosis in Elderly Patients with NonSTSegment Elevation Myocardial Infarction, "Polish Archives of Internal Medicine” 2012; 122 (6): 253-261, doi: 10.20452/pamw.1285.
Przybysz-Zdunek B., Ploch M., Pluta W., et al., All-cause Readmission and Repeat Revascularization after Percutaneous Coronary Intervention, "Journal of Cardiology” 2012; 19 (2): 174-179, doi: 10.5603/cj.2012.0030.